Detail of "198153-51-4"

CAS Number:
198153-51-4
Name:
InterferonaA (human leukocyte),mono(N2,N6-dicarboxy-L-lysyl) deriv., diester with a-methyl-w-hydroxypoly(oxy-1,2-ethanediyl)(9CI)
Deleted CAS:
330464-33-0
Synonyms:
Pegasys;Peginterferon a-2a;Peginterferonalfa-2a;Peginterferon alpha-2A;Ro 25-8310/000;

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Pegylated interferons: pharmacological basis: Pegylated interferons: pharmacological basis. Macquin-Mavier, Isabelle; Hezode, Christophe; Dhumeaux, Daniel ( Service de Pharmacologie Clinique, CHU Henri Mondor, Assistance Publique, Hopitaux de Paris, Creteil 94000, Fr.). Gastroenterologie Clinique et Biologique, 26(8-9), 742-747 (French) 2002 Masson Editeur. CODEN: GCBIDC. ISSN: 0399-8320. DOCUMENT TYPE: Journal; General Review CA Section: 15 (Immunochemistry) Section cross-reference(s): 1 A review. Discussed are: pegylation of proteins (principles of pegylation; influence of pegylation on pharmacokinetic and pharmacodynamic properties of proteins; clin. advantages of pegylation of proteins); and pegylated interferons a2 (structure; pharmacokinetics; pharmacodynamic properties; influence of physiol. or pathol. conditions on the pharmacokinetics of pegylated interferon a2; drug interactions). 198153-51-4 and 215647-85-1 are just another two chemicals used in this study. .

Pharmacokinetics of ribavirin in patients with hepatitis C virus: All Rights Reserved. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Wade, Janet R.; Snoeck, Eric; Duff, Frank; Lamb, Matthew; Jorga, Karin (Exprimo NV, Lummen, Belg.). British Journal of Clinical Pharmacology, 62(6), 710-714 (English) 2006 Blackwell Publishing Ltd. CODEN: BCPHBM. ISSN: 0306-5251. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Aim A population pharmacokinetic anal. was performed using plasma concn. data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics. Methods Ribavirin pharmacokinetics were described by a three-compartment model with sequential zero-order and a first-order absorption processes. Interoccasion variability and food effects were included. Results Lean body wt. 36791-04-5 and 198153-51-4 are also in the experiment. (range 41-91 kg) was the only covariate with a clin. significant influence on ribavirin pharmacokinetics, affecting clearance (15.3-23.9 l h-1) and the vol. of the larger peripheral compartment. Conclusion The model provided a good description of the available data, confirmed by accurate ests. of parameter values and low residual variability (17%). .